Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

603

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Healthy

Interventions

BIOLOGICAL

M923

Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)

Trial Locations (2)

QOPK Phase 1 Clinic, Overland Park

QLON Phase 1 Clinic, London